Apellis Pharmaceuticals’ (APLS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS) in a research report released on Friday, Benzinga reports. The firm currently has a $92.00 target price on the stock.

A number of other research analysts have also weighed in on APLS. UBS Group increased their price objective on Apellis Pharmaceuticals from $87.00 to $89.00 and gave the company a buy rating in a report on Monday, March 4th. Wedbush cut their price objective on Apellis Pharmaceuticals from $67.00 to $57.00 and set a neutral rating on the stock in a report on Wednesday, April 17th. Robert W. Baird reissued an outperform rating and issued a $81.00 price objective on shares of Apellis Pharmaceuticals in a report on Tuesday, February 6th. Oppenheimer increased their price objective on Apellis Pharmaceuticals from $75.00 to $79.00 and gave the company an outperform rating in a report on Tuesday, January 30th. Finally, Mizuho reaffirmed a neutral rating and set a $60.00 target price on shares of Apellis Pharmaceuticals in a report on Wednesday, March 27th. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Apellis Pharmaceuticals has a consensus rating of Moderate Buy and an average target price of $77.93.

Apellis Pharmaceuticals Trading Up 4.0 %

Shares of NASDAQ:APLS opened at $49.86 on Friday. The business’s 50-day moving average is $57.84 and its 200 day moving average is $57.53. Apellis Pharmaceuticals has a 1 year low of $19.83 and a 1 year high of $94.75. The firm has a market capitalization of $6.01 billion, a P/E ratio of -11.13 and a beta of 0.88. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.10 and a quick ratio of 2.50.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Tuesday, February 27th. The company reported ($0.73) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.73). Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The company had revenue of $146.38 million for the quarter, compared to analyst estimates of $143.34 million. During the same period in the prior year, the company posted ($1.50) EPS. The firm’s quarterly revenue was up 545.9% compared to the same quarter last year. On average, research analysts predict that Apellis Pharmaceuticals will post -1.34 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Adam J. Townsend sold 1,148 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $67.77, for a total value of $77,799.96. Following the transaction, the insider now owns 92,453 shares in the company, valued at $6,265,539.81. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider Adam J. Townsend sold 1,148 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $67.77, for a total value of $77,799.96. Following the transaction, the insider now owns 92,453 shares in the company, valued at $6,265,539.81. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Pascal Deschatelets sold 69,107 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $54.17, for a total value of $3,743,526.19. Following the completion of the transaction, the insider now owns 1,115,983 shares in the company, valued at approximately $60,452,799.11. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 376,427 shares of company stock worth $23,169,639. 7.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in APLS. First Horizon Advisors Inc. lifted its position in Apellis Pharmaceuticals by 69.0% during the third quarter. First Horizon Advisors Inc. now owns 649 shares of the company’s stock worth $25,000 after buying an additional 265 shares in the last quarter. Future Financial Wealth Managment LLC purchased a new position in Apellis Pharmaceuticals during the first quarter worth approximately $29,000. Covestor Ltd lifted its position in Apellis Pharmaceuticals by 564.2% during the third quarter. Covestor Ltd now owns 797 shares of the company’s stock worth $30,000 after buying an additional 677 shares in the last quarter. Stephens Consulting LLC purchased a new position in Apellis Pharmaceuticals during the third quarter worth approximately $38,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in Apellis Pharmaceuticals by 29.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,028 shares of the company’s stock worth $115,000 after buying an additional 687 shares in the last quarter. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).